Total global spending on oncology medicines – including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, while spending on oncology drugs in the U.S. increased 5.3 percent compounded annual...
BLOG: Pharmacogenomics is the study of how DNA differences affect response to medications. This can explain why similar patients have different reactions to the same medication even if they receive the same dosage. The...
Several weight loss and fitness supplements contain the chemical BMPEA, a stimulant similar to amphetamine, according to a new study.
Currently, the IBS treatment market is naïve and underpenetrated, with only 4 products indicated for IBS in the 7MM.
Managed care and hospital decision-makers are in a key position to “move the needle” at the system level on improving adult immunization coverage rates in the United States.
More than one-third of reproductive-aged women enrolled in Medicaid, and more than a quarter of those with private insurance, filled a prescription for an opioid pain medication each year during 2008 to 2012, according to a recent...

FDA APPROVALS
FDA drug approvals-May 2015

FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations

Long-acting schizophrenia drug may ...
Pediatric migraine drug gets FDA ...
New antibacterial treatment for ...

CLINICAL
FDA drug approvals-May 2015

FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations

J&J-Achillion partner to develop ...
Long-acting schizophrenia drug may ...
Biosimilars need better labeling: ...

DRUGS IN PERSPECTIVE
Drugs in Perspective: Opdivo (nivolumab)

On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the ...

Drugs in Perspective: Myalept ...
Drugs in Perspective: Otezla ...
Drugs in Perspective: Zykadia ...

Latest Tweets Follow

Poll

View Results